STUDIES OF CENTRAL NERVOUS SYSTEM FUNCTIONAL ANATOMY
中枢神经系统功能解剖学研究
基本信息
- 批准号:5203682
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer's disease Huntington's disease antidepressants brain mapping brain stem cannabinoids central nervous system corticotropin releasing factor cytokine drug receptors electroconvulsive therapy human tissue hypothalamic pituitary axis interleukin 1 locus coeruleus neuroanatomy neuroendocrine system neuropeptides neurotransmitter receptor paraventricular nucleus stress
项目摘要
The Section on Functional Neuroanatomy combines molecular and
neuroanatomical methods to identify dynamic aspects of nervous system
function that relate to issues of mental health, infectious disease, and
drug abuse. Drug and neurotransmitter receptors are mapped using in
vitro ligand binding and autoradiography. In situ hybridization
histochemistry is used to localize and quantify mRNA expression of
neuropeptides, monoamine transporters and synthesizing enzymes,
receptors, cytokines, and immediate-early genes in studies of adaptive
changes to behavioral, pharmacological, or surgical interventions. 1)
The cannabinoid receptor has been localized and quantified in
Huntington's and Alzheimer's brains. 2) Studies of animal models of
chronic stress are designed to elucidate brain mechanisms involved in the
therapeutic amelioration of stress disorders. Antidepressant drug
administration and electroconvulsive shock are used in the animal models.
Brain systems responsive to both stress and therapeutic treatment include
the corticotropin-releasing hormone (CRH) component of the hypothalamic
paraventricular nucleus (PVN), which controls the hypothalamic-pituitary-
adrenal axis, and the noradrenergic locus coeruleus, which plays a role
in arousal and vigilance. 3) Expression of the mRNA for the immediate-
early gene c-fos was used to map brain sites responsive to injections of
interleukin-1. Responsive cells in the brainstem suggest a pathway by
which peripheral cytokines, as mediators of immune or inflammatory
challenges, affect neuroendocrine responses. 4) Combinations of
anatomical markers are used to reveal activity changes in hypothalamic
arcuate nucleus neurons with known neuropeptide phenotype and identified
projections to the PVN.
功能神经解剖学部分结合了分子和
神经解剖学方法,以确定神经系统的动态方面
与心理健康、传染病和
吸毒 药物和神经递质受体的映射使用在
体外配体结合和放射自显影。 原位杂交
组织化学用于定位和定量
神经肽、单胺转运蛋白和合成酶,
受体、细胞因子和即刻早期基因在适应性
行为、药物或手术干预的变化。 第一章
大麻素受体已被定位和量化,
亨廷顿舞蹈症和老年痴呆症的大脑。 2)动物模型的研究
慢性压力旨在阐明大脑机制参与
治疗性改善应激障碍。 抗抑郁药物
给药和电休克用于动物模型。
对压力和治疗都有反应的大脑系统包括
下丘脑的促肾上腺皮质激素释放激素(CRH)成分
室旁核(PVN),控制下丘脑-垂体-
肾上腺轴,和去甲肾上腺素能蓝斑,其中发挥作用,
唤醒和警惕。 3)表达的mRNA的立即-
早期基因c-fos被用来绘制大脑部位对注射
白细胞介素-1。 脑干中的反应细胞表明,
外周细胞因子,作为免疫或炎症介质,
挑战,影响神经内分泌反应。 4)的组合
解剖学标记用于揭示下丘脑的活动变化,
已知神经肽表型的弓状核神经元,
预测PVN。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M HERKENHAM其他文献
M HERKENHAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M HERKENHAM', 18)}}的其他基金
相似海外基金
Exploring the role of epigenetic mechanisms in the manifestation of Huntington's disease
探索表观遗传机制在亨廷顿舞蹈病表现中的作用
- 批准号:
MR/Y014685/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease
通过源自工程化人类 iPS 细胞的外泌体向大脑靶向递送治疗分子:亨廷顿病的潜在治疗方法
- 批准号:
10588392 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Emerging role of glymphatic clearance in Huntington's disease
类淋巴清除在亨廷顿病中的新作用
- 批准号:
10599627 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Project 3: Therapeutic Gene Editing for Huntington's Disease
项目3:亨廷顿病的治疗性基因编辑
- 批准号:
10668769 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Characterizing GABAergic transmission at the cellular and synaptic levels in the developing and mature basal ganglia of the Huntington's Disease brain
描述亨廷顿病大脑发育和成熟基底神经节细胞和突触水平上的 GABA 能传递
- 批准号:
478477 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Using genetic modifiers to identify and target pathogenic mechanisms in Huntington's disease
使用遗传修饰剂来识别和靶向亨廷顿病的致病机制
- 批准号:
MR/X018253/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship
Repeat-induced mutagenesis in Huntington's disease
亨廷顿病的重复诱导突变
- 批准号:
MR/X02184X/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Research Grant
Elucidating Semaphorin-6D Signaling Axis in Huntington's Disease
阐明亨廷顿病中的 Semaphorin-6D 信号轴
- 批准号:
23K14503 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Modulation of Somatic Repeat Expansion as a Therapeutic Approach to Huntington's Disease
调节体细胞重复扩增作为亨廷顿病的治疗方法
- 批准号:
10678016 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Identifying New Astrocytic Kir4.1 Channel Modulators for Treating Huntington's Disease
鉴定用于治疗亨廷顿病的新型星形细胞 Kir4.1 通道调节剂
- 批准号:
10681097 - 财政年份:2023
- 资助金额:
-- - 项目类别: